CRISPR Therapeutics Announces Transition of Chief Operating Officer
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.
Positive
- None.
Negative
- Departure of key executive (COO) could create temporary leadership gap
- Loss of experienced leader who advanced critical hematology and oncology programs
News Market Reaction
On the day this news was published, CRSP declined 2.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025.
“Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “I want to thank her for her contributions and wish her all the best in her future endeavors and continued success.”
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics COO Julianne Bruno leaving the company?
How long has Julianne Bruno served as COO at CRISPR Therapeutics (CRSP)?
What were Julianne Bruno's main achievements at CRISPR Therapeutics (CRSP)?
Has CRISPR Therapeutics (CRSP) announced a replacement for the departing COO?
